{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:44Z","timestamp":1789785344750,"version":"4.0.1"},"reference-count":103,"publisher":"Rockefeller University Press","issue":"10","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,9,21]]},"abstract":"<jats:p>The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent on BCR-ABL, additional mutations are required for progression to BC. However, the identity of these mutations and the pathways they affect are poorly understood, hampering our ability to identify therapeutic targets and improve outcomes. Here, we describe a novel mouse model that allows identification of mechanisms of BC progression in an unbiased and tractable manner, using transposon-based insertional mutagenesis on the background of chronic phase CML. Our BC model is the first to faithfully recapitulate the phenotype, cellular and molecular biology of human CML progression. We report a heterogeneous and unique pattern of insertions identifying known and novel candidate genes and demonstrate that these pathways drive disease progression and provide potential targets for novel therapeutic strategies. Our model greatly informs the biology of CML progression and provides a potent resource for the development of candidate therapies to improve the dismal outcomes in this highly aggressive disease.<\/jats:p>","DOI":"10.1084\/jem.20141661","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T01:13:54Z","timestamp":1440465234000},"page":"1551-1569","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression"],"prefix":"10.1084","volume":"212","author":[{"given":"George","family":"Giotopoulos","sequence":"first","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"van der Weyden","sequence":"additional","affiliation":[{"name":"Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Osaki","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G.","family":"Rust","sequence":"additional","affiliation":[{"name":"Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK 3"},{"name":"Tumour Profiling Unit, The Institute of Cancer Research, Chester Beatty Laboratories, London SW3 6JB, England, UK 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshwar","family":"Meduri","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-In","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rab K.","family":"Prinjha","sequence":"additional","affiliation":[{"name":"Epinova DPU, GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, England, UK 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Pimanda","sequence":"additional","affiliation":[{"name":"Lowy Cancer Research Centre and the Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Tenen","sequence":"additional","affiliation":[{"name":"Cancer Science Institute, National University of Singapore, Singapore 119077 7"},{"name":"Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, England, UK 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52062 Aachen, Germany 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Adams","sequence":"additional","affiliation":[{"name":"Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK 1"},{"name":"Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2015,8,24]]},"reference":[{"key":"2023072602463291500_bib1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell."},{"key":"2023072602463291500_bib2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"2023072602463291500_bib3","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.86.17.6783","article-title":"Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia","volume":"86","author":"Ahuja","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature."},{"key":"2023072602463291500_bib5","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood."},{"key":"2023072602463291500_bib6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia."},{"key":"2023072602463291500_bib7","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood."},{"key":"2023072602463291500_bib8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib9","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood."},{"key":"2023072602463291500_bib10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.V90.6.2168","article-title":"A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product","volume":"90","author":"Castellanos","year":"1997","journal-title":"Blood."},{"key":"2023072602463291500_bib11","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/MCB.05830-11","article-title":"The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells","volume":"31","author":"Chan","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"2023072602463291500_bib12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics."},{"key":"2023072602463291500_bib13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"2023072602463291500_bib14","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood."},{"key":"2023072602463291500_bib15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature."},{"key":"2023072602463291500_bib16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science."},{"key":"2023072602463291500_bib17","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1073\/pnas.102583199","article-title":"A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOXA9","volume":"99","author":"Dash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature."},{"key":"2023072602463291500_bib19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib20","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2023072602463291500_bib21","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1371\/journal.pcbi.0020166","article-title":"Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens","volume":"2","author":"de Ridder","year":"2006","journal-title":"PLOS Comput. Biol."},{"key":"2023072602463291500_bib22","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood."},{"key":"2023072602463291500_bib23","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood-2012-07-446120","article-title":"Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia","volume":"121","author":"Diffner","year":"2013","journal-title":"Blood."},{"key":"2023072602463291500_bib24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"2023072602463291500_bib25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib26","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bcmd.2013.09.002","article-title":"Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy","volume":"52","author":"Ferri","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"2023072602463291500_bib28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"1995","journal-title":"Blood."},{"key":"2023072602463291500_bib29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2141.2011.08653.x","article-title":"Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study","volume":"155","author":"Gallipoli","year":"2011","journal-title":"Br. J. Haematol."},{"key":"2023072602463291500_bib30","first-page":"32","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo","volume":"21","author":"Gallipoli","year":"2014","journal-title":"Blood."},{"key":"2023072602463291500_bib31","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1182\/blood-2013-01-477133","article-title":"Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia","volume":"122","author":"Goldberg","year":"2013","journal-title":"Blood."},{"key":"2023072602463291500_bib32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia."},{"key":"2023072602463291500_bib33","first-page":"1034","article-title":"Expression of GATA-1 mRNA in human myeloid leukemic cells","volume":"8","author":"Guerrasio","year":"1994","journal-title":"Leukemia."},{"key":"2023072602463291500_bib34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"2023072602463291500_bib35","first-page":"2798","article-title":"A bcr-v-abl oncogene induces lymphomas in transgenic mice","volume":"9","author":"Hariharan","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"2023072602463291500_bib36","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica."},{"key":"2023072602463291500_bib37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood."},{"key":"2023072602463291500_bib38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature."},{"key":"2023072602463291500_bib39","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V91.6.2067","article-title":"Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr\/abl: a novel transgenic model for human Ph1-positive leukemias","volume":"91","author":"Honda","year":"1998","journal-title":"Blood."},{"key":"2023072602463291500_bib40","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood."},{"key":"2023072602463291500_bib41","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4238\/2014.February.19.5","article-title":"Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing","volume":"13","author":"Huang","year":"2014","journal-title":"Genet. Mol. Res."},{"key":"2023072602463291500_bib42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat. Genet."},{"key":"2023072602463291500_bib43","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1182\/blood-2003-03-0768","article-title":"Inducible expression of BCR\/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome","volume":"102","author":"Huettner","year":"2003","journal-title":"Blood."},{"key":"2023072602463291500_bib44","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib46","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood."},{"key":"2023072602463291500_bib47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.leukres.2009.11.008","article-title":"Molecular characterization and prognostic significance of FLT3 in CML progression","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk. Res."},{"key":"2023072602463291500_bib48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V100.1.238","article-title":"Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice","volume":"100","author":"Kogan","year":"2002","journal-title":"Blood."},{"key":"2023072602463291500_bib49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia."},{"key":"2023072602463291500_bib50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood."},{"key":"2023072602463291500_bib51","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1158\/0008-5472.CAN-11-0176","article-title":"Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias","volume":"71","author":"Kvinlaug","year":"2011","journal-title":"Cancer Res."},{"key":"2023072602463291500_bib52","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2007-08-105072","article-title":"Requirement of c-Myb for p210(BCR\/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis","volume":"111","author":"Lidonnici","year":"2008","journal-title":"Blood."},{"key":"2023072602463291500_bib53","doi-asserted-by":"publisher","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","journal-title":"Mol. Cancer."},{"key":"2023072602463291500_bib55","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood."},{"key":"2023072602463291500_bib56","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/ng.990","article-title":"Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis","volume":"43","author":"March","year":"2011","journal-title":"Nat. Genet."},{"key":"2023072602463291500_bib57","doi-asserted-by":"publisher","first-page":"9234","DOI":"10.1200\/JCO.2005.03.6137","article-title":"Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2023072602463291500_bib58","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J."},{"key":"2023072602463291500_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1601-5223.1978.tb01277.x","article-title":"Clustering of aberrations to specific chromosomes in human neoplasms. III. Incidence and geographic distribution of chromosome aberrations in 856 cases","volume":"89","author":"Mitelman","year":"1978","journal-title":"Hereditas."},{"key":"2023072602463291500_bib60","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1182\/blood-2007-05-088724","article-title":"Enhanced expression of p210BCR\/ABL and aberrant expression of Zfp423\/ZNF423 induce blast crisis of chronic myelogenous leukemia","volume":"113","author":"Miyazaki","year":"2009","journal-title":"Blood."},{"key":"2023072602463291500_bib61","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1038\/sj.onc.1211007","article-title":"Overexpression\/enhanced kinase activity of BCR\/ABL and altered expression of Notch1 induced acute leukemia in p210BCR\/ABL transgenic mice","volume":"27","author":"Mizuno","year":"2008","journal-title":"Oncogene."},{"key":"2023072602463291500_bib62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1182\/blood.V100.1.246","article-title":"Bethesda proposals for classification of lymphoid neoplasms in mice","volume":"100","author":"Morse","year":"2002","journal-title":"Blood."},{"key":"2023072602463291500_bib63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0092-8674(91)90099-K","article-title":"A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis","volume":"65","author":"Mucenski","year":"1991","journal-title":"Cell."},{"key":"2023072602463291500_bib64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature."},{"key":"2023072602463291500_bib65","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2007-02-073031","article-title":"Leukemia stem cells in a genetically defined murine model of blast-crisis CML","volume":"110","author":"Neering","year":"2007","journal-title":"Blood."},{"key":"2023072602463291500_bib66","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2023072602463291500_bib67","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood."},{"key":"2023072602463291500_bib68","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood."},{"key":"2023072602463291500_bib69","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"142","author":"Nowell","year":"1960","journal-title":"Science."},{"key":"2023072602463291500_bib70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2023072602463291500_bib71","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood."},{"key":"2023072602463291500_bib72","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2023072602463291500_bib73","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/leu.2009.95","article-title":"Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia","volume":"23","author":"Piccaluga","year":"2009","journal-title":"Leukemia."},{"key":"2023072602463291500_bib74","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature."},{"key":"2023072602463291500_bib75","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature."},{"key":"2023072602463291500_bib76","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The Biology of CML blast crisis","volume":"2007","author":"Radich","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"key":"2023072602463291500_bib77","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib78","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors","volume":"64","author":"Ramaraj","year":"2004","journal-title":"Cancer Res."},{"key":"2023072602463291500_bib79","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1541-7786.MCR-13-0244","article-title":"Cancer gene discovery: exploiting insertional mutagenesis","volume":"11","author":"Ranzani","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"2023072602463291500_bib80","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1182\/blood.V79.8.1956.1956","article-title":"Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides","volume":"79","author":"Ratajczak","year":"1992","journal-title":"Blood."},{"key":"2023072602463291500_bib81","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2141.2008.07474.x","article-title":"In vitro anti-leukaemia activity of sphingosine kinase inhibitor","volume":"144","author":"Ricci","year":"2009","journal-title":"Br. J. Haematol."},{"key":"2023072602463291500_bib82","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"key":"2023072602463291500_bib83","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1242\/dev.126.17.3891","article-title":"An SCL 3\u2032 enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors","volume":"126","author":"S\u00e1nchez","year":"1999","journal-title":"Development."},{"key":"2023072602463291500_bib84","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood."},{"key":"2023072602463291500_bib85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/nar\/29.2.397","article-title":"The transcriptional program of a human B cell line in response to Myc","volume":"29","author":"Schuhmacher","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"2023072602463291500_bib86","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer."},{"key":"2023072602463291500_bib87","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood.V86.8.3173.3173","article-title":"The expression pattern of erythrocyte\/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia","volume":"86","author":"Shimamoto","year":"1995","journal-title":"Blood."},{"key":"2023072602463291500_bib88","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia","volume":"85","author":"Sill","year":"1995","journal-title":"Blood."},{"key":"2023072602463291500_bib89","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica."},{"key":"2023072602463291500_bib90","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.V87.4.1539.bloodjournal8741539","article-title":"Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis","volume":"87","author":"Sirard","year":"1996","journal-title":"Blood."},{"key":"2023072602463291500_bib91","doi-asserted-by":"publisher","first-page":"13137","DOI":"10.1073\/pnas.93.23.13137","article-title":"Blastic transformation of p53-deficient bone marrow cells by p210bcr\/abl tyrosine kinase","volume":"93","author":"Skorski","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jcp.20210","article-title":"Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development","volume":"203","author":"Smith","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"2023072602463291500_bib93","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602463291500_bib94","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood."},{"key":"2023072602463291500_bib95","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nprot.2009.64","article-title":"A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites","volume":"4","author":"Uren","year":"2009","journal-title":"Nat. Protoc."},{"key":"2023072602463291500_bib96","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1182\/blood-2011-02-338848","article-title":"Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice","volume":"118","author":"van der Weyden","year":"2011","journal-title":"Blood."},{"key":"2023072602463291500_bib97","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/ng.796","article-title":"Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice","volume":"43","author":"Vassiliou","year":"2011","journal-title":"Nat. Genet."},{"key":"2023072602463291500_bib98","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V91.7.2406","article-title":"High level engraftment of NOD\/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase","volume":"91","author":"Wang","year":"1998","journal-title":"Blood."},{"key":"2023072602463291500_bib99","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Warsch","year":"2013","journal-title":"Blood."},{"key":"2023072602463291500_bib100","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1084\/jem.20041247","article-title":"Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia","volume":"200","author":"Yasuda","year":"2004","journal-title":"J. Exp. Med."},{"key":"2023072602463291500_bib101","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood.V97.8.2406","article-title":"A model of human p210(bcr\/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR\/ABL-containing retroviral vector","volume":"97","author":"Zhao","year":"2001","journal-title":"Blood."},{"key":"2023072602463291500_bib102","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1182\/blood-2011-08-370981","article-title":"Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood."},{"key":"2023072602463291500_bib103","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/212\/10\/1551\/1752644\/jem_20141661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/212\/10\/1551\/1752644\/jem_20141661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T02:47:34Z","timestamp":1690339654000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/212\/10\/1551\/41686\/A-novel-mouse-model-identifies-cooperating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,24]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,9,21]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20141661","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,24]]}}}